Skip to main content
. Author manuscript; available in PMC: 2016 Mar 30.
Published in final edited form as: Curr Mol Med. 2016;16(3):222–231. doi: 10.2174/1566524016666160225151131

Table 2.

Receptor prevalence.

Receptors Total (N)
Presence of Type I receptors, n (%)
 ALK2 241/242 (99.6%)
 ALK3 240/251 (95.6%)
 ALK6 111/249 (44.6%)
Presence of Type II receptor, n (%) † 185/252 (73.4%)
Combinations
 MISR2, ALK2, ALK3, ALK6 84/235 (36%)
 MISR2, ALK2, and ALK3 81/235 (34%)
 ALK2 and ALK3 43/235 (18%)
 ALK2, ALK3, and ALK6 16/235 (6.8%)
 MISR2 and ALK2 6 (2.5%)
 MISR2, ALK2, and ALK6 4 (1.7%)
 ALK2 present only 1 (0.4%)
 At least one of the 4 receptors was non-diagnostic 27 (11.4%)
†

Percentage of the patients with a diagnostic result for each specific receptor.